CD22 and systemic lupus erythematosus: A post-hoc analysis of the Phase III trial showed improved SLE disease activity in response to Emab in a subgroup of SLE patients with associated Sjogren's Syndrome (SjS), suggesting a future use of Emab (123) or other CD22-based drugs.